Evidence map›Paper›PMID 39844122›Full record

ArticleBMC public health2025

Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis.

Jay P Bae, David R Nelson, Kristina S Boye, Kieren J Mather

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Serum zinc, copper status and Cu/Zn ratio in overweight and obesity: associations with oxidative stress, adipokines, and cardiometabolic traits in adult women.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Trends in Diagnosing Obesity: The CALOR Study.Obesity (Silver Spring, Md.) · 2026
    Article
  9. Article
  10. Article
  11. Palmitoylethanolamide in Human and Animal Obesity.Molecules (Basel, Switzerland) · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jay P BaeEli Lilly and Company, Indianapolis, IN, 46285, USA. bae_jay@lilly.com.
David R NelsonEli Lilly and Company, Indianapolis, IN, 46285, USA.
Kristina S BoyeEli Lilly and Company, Indianapolis, IN, 46285, USA.
Kieren J MatherEli Lilly and Company, Indianapolis, IN, 46285, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the substantial burden of obesity in the United States (US), data on the comprehensive range of comorbidities in different age groups is limited. This study assessed the prevalence of various comorbidities among people diagnosed with obesity (as per ICD-10 diagnosis code) across age cohorts and compared how they differ from people without obesity.

methodsThis cross-sectional study analyzed individuals from all four regions (Midwest, Northeast, South, and West) of the US who had continuous insurance coverage from 2018 to 2020, using a large health insurance claims database (Merative™ MarketScan

resultsOf 6,935,911 individuals, people with a diagnosis of obesity accounted for 22.0%, 33.6%, and 34.4% in the 18-39 years, 40-64 years, and ≥ 65 years age groups, respectively. Within age strata, the mean age of people with obesity was comparable with those without obesity. Comorbidity burden was significantly higher among people with obesity, but increased with age in both obesity and non-obesity groups. Comorbidities with highest prevalence in people with obesity included: (i) hypertension (18-39 years: 29.0%, 40-64 years: 66.2%, ≥ 65 years: 89.4%), (ii) dyslipidemia (18-39 years: 28.1%, 40-64 years: 65.4%, ≥ 65 years: 88.0%), (iii) depression or anxiety (18-39 years: 44.1%, 40-64 years: 39.0%, ≥ 65 years: 38.9%), and (iv) prediabetes (18-39 years: 17.1%, 40-64 years: 32.2%, ≥ 65 years: 35.3%). Notably, increased prevalence of cardiometabolic risk factors such as hypertension and dyslipidemia began at an earlier age in people with obesity as compared with those without obesity. Ratio of prevalence between obesity and non-obesity groups was highest for the 18-39 years age group, as compared to older groups. Disorders such as obstructive sleep apnea, osteoarthritis, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, coronary heart diseases (CHD), and chronic kidney diseases also exhibited substantial burden among those with obesity.

conclusionsIn this claims study, hypertension and dyslipidemia were the leading comorbidities in people with obesity, with an increasing prevalence with age. The burden of cardiometabolic comorbidities among the younger age group suggested potential risk for early onset of CHD in later life. Understanding the range of obesity-related comorbidities seen in this claims data may encourage healthcare professionals and healthcare systems to systematically diagnose and better manage these disorders. Further research using additional data sources can offer a more accurate view of the prevalence of obesity and its impact.

Indexed as

ComorbidityInsurance Claim ReviewInsurance, HealthObesityAdolescentAdultAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedPrevalenceUnited StatesYoung AdultCardiovascular diseasesComorbiditiesDyslipidemiaHypertensionObesity

Identifiers

PMID39844122
PMCPMC11756071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.